sulpiride has been researched along with Parkinson Disease, Secondary in 27 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulpiride is an important tool for elucidating both the practical and heuristic aspects of subtypes of dopamine receptors and is a lead in the search for compounds that selectively affect dopaminergic mechanisms." | 2.65 | Sulpiride in tardive dyskinesia. ( Casey, DE; Gerlach, J; Simmelsgaard, H, 1979) |
| " Simultaneous administration of (+)-PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] and CY 208-243 [(-)4,6,6a,7,8,12b-hexahydro-7-methylindolo[4,3a-b]phenan thyxidine] did not result in modification of the dose-response curve induced by each dopamine receptor agonist given alone." | 1.29 | Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys. ( Guillén, J; Laguna, J; Luquin, MR; Martínez-Lage, JM; Martínez-Vila, E, 1994) |
| "Sulpiride has the same possible side effects than classic neuroleptics." | 1.29 | Tardive akathisia due to sulpiride. ( Arce, A; Gorospe, A; López de Munain, A; Martí Massó, JF; Poza, JJ, 1994) |
| "Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) may be classified into three main categories: "On" dyskinesias, diphasic dyskinesias (DD), and "off" periods." | 1.28 | Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. ( Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (29.63) | 18.7374 |
| 1990's | 16 (59.26) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, JH | 1 |
| Cho, H | 1 |
| Kim, YJ | 1 |
| Kim, JS | 1 |
| Baik, JS | 1 |
| Jang, S | 1 |
| Ma, HI | 1 |
| Saft, C | 1 |
| Andrich, J | 1 |
| Kraus, PH | 1 |
| Przuntek, H | 1 |
| Gerlach, J | 3 |
| Casey, DE | 2 |
| Munk-Andersen, E | 1 |
| Behnke, K | 1 |
| Heltberg, J | 1 |
| Nielsen, H | 1 |
| Franchignoni, FP | 1 |
| Tesio, L | 1 |
| Akai, T | 1 |
| Ozawa, M | 1 |
| Yamaguchi, M | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Luquin, MR | 2 |
| Guillén, J | 1 |
| Martínez-Vila, E | 1 |
| Laguna, J | 1 |
| Martínez-Lage, JM | 1 |
| Sato, K | 1 |
| Ueda, H | 1 |
| Okumura, F | 1 |
| Misu, Y | 1 |
| Graham, WC | 4 |
| Sambrook, MA | 3 |
| Crossman, AR | 4 |
| Bodis-Wollner, I | 1 |
| Tagliati, M | 1 |
| Martí Massó, JF | 2 |
| Poza, JJ | 2 |
| Benazzi, F | 1 |
| Calabresi, P | 1 |
| Saiardi, A | 1 |
| Pisani, A | 1 |
| Baik, JH | 1 |
| Centonze, D | 1 |
| Mercuri, NB | 1 |
| Bernardi, G | 1 |
| Borrelli, E | 1 |
| López de Munain, A | 1 |
| Gorospe, A | 1 |
| Arce, A | 1 |
| Murer, MG | 1 |
| Dziewczapolski, G | 1 |
| Menalled, LB | 1 |
| García, MC | 1 |
| Agid, Y | 1 |
| Gershanik, O | 2 |
| Raisman-Vozari, R | 1 |
| Giladi, N | 1 |
| Melamed, E | 1 |
| Teive, HA | 1 |
| Sa, DS | 1 |
| Simmelsgaard, H | 1 |
| Dufour, H | 1 |
| Castelli, J | 1 |
| Luccioni, H | 1 |
| Scotto, JC | 1 |
| Sutter, JM | 1 |
| Scipioni, O | 1 |
| Vaamonde, J | 1 |
| Obeso, JA | 1 |
| Hill, DR | 1 |
| Woodruff, GN | 3 |
| Clarke, CE | 1 |
| Boyce, S | 1 |
| Bédard, PJ | 1 |
| Boucher, R | 1 |
| Temlett, JA | 1 |
| Chong, PN | 1 |
| Oertel, WH | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Chouza, C | 1 |
| Caamano, JL | 1 |
| Romero, S | 1 |
| Lorenzo, J | 1 |
| Feres, S | 1 |
| Brion, S | 1 |
| Guérin, R | 1 |
4 trials available for sulpiride and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report.
Topics: Adult; Autonomic Nervous System; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; | 1984 |
Sulpiride in tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Female; Humans; Male | 1979 |
[A new substituted benzamide with neuroleptic effects: lin 14 18 or sultopride].
Topics: Adult; Aged; Benzamides; Clinical Trials as Topic; Delusions; Drug Evaluation; Humans; Male; Middle | 1975 |
[Combination of L-dopa and sulpiride in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Interactions; Dru | 1973 |
23 other studies available for sulpiride and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Trends in the Prevalence of Drug-Induced Parkinsonism in Korea.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Benzyl Compounds; Drug Prescriptions; Femal | 2019 |
[Amisulpride in Huntington's disease].
Topics: Aged; Amisulpride; Antipsychotic Agents; Delusions; Dose-Response Relationship, Drug; Drug Administr | 2005 |
Sulpiride in tardive dyskinesia.
Topics: Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Parkinson Disease, Sec | 1984 |
[Parkinson syndrome induced by veralipride].
Topics: Dopamine Antagonists; Female; Humans; Menopause; Middle Aged; Parkinson Disease, Secondary; Sulpirid | 1995 |
Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Disease Models | 1995 |
Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
Topics: Animals; Benzazepines; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship | 1994 |
Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetylcholine; Animals; Benzazepines; Do | 1994 |
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Topics: Animals; Apomorphine; Autoradiography; Benzazepines; Brain Chemistry; Caudate Nucleus; Dopamine Agen | 1993 |
The visual system in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Contrast Sensitivity; Dopamine; Electroenceph | 1993 |
[Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs].
Topics: Adult; Aged; Antiemetics; Antipsychotic Agents; Cinnarizine; Female; Flupenthixol; Follow-Up Studies | 1996 |
Side-effects of benzamide derivatives.
Topics: Depressive Disorder; Dopamine Antagonists; Female; Humans; Middle Aged; Parkinson Disease, Secondary | 1997 |
Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cerebral Cortex; Corpus | 1997 |
Tardive akathisia due to sulpiride.
Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dopamine An | 1994 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease | 1998 |
Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism.
Topics: Aged; Antiparkinson Agents; Blepharospasm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middl | 1999 |
Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.
Topics: Dopamine Antagonists; Female; Humans; Menopause; Middle Aged; Parkinson Disease; Parkinson Disease, | 2001 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Dr | 1992 |
Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzodiazepinones; Cholecyst | 1991 |
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat.
Topics: Animals; Benzazepines; Corpus Striatum; Hydroxydopamines; Male; Neurotoxins; Oxidopamine; Parkinson | 1990 |
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis).
Topics: Animals; Benzazepines; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Rece | 1990 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1989 |
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Callitrichinae; Dopamine Antago | 1988 |
Extrapyramidal effects of benzamides.
Topics: Basal Ganglia Diseases; Benzamides; Dyskinesia, Drug-Induced; Humans; Metoclopramide; Movement Disor | 1985 |